Renalis
A digital health company creating platforms to improve experiences and outcomes for people with pelvic health conditions.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
* | N/A | - | |
| Total Funding | 000k | ||
| USD | 2021 | 2023 |
|---|---|---|
| Revenues | 0000 | 0000 |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Renalis is a digital health company specializing in the development of Prescription Digital Therapeutics (PDTs) aimed at treating pelvic health disorders. The company's flagship product, CeCe, is a mobile-enhanced digital therapeutic designed for the first-line treatment of overactive bladder (OAB) in individuals assigned female at birth. Renalis operates in the digital health market, focusing on providing evidence-based therapeutic interventions through software applications that are prescribed by clinicians. The business model revolves around creating and distributing these digital therapeutics, which are monetized through partnerships with healthcare providers and direct sales to medical institutions. Renalis serves a niche market of patients with specific pelvic health needs, leveraging technology to offer innovative treatment solutions. The company generates revenue by licensing its software to healthcare providers and through direct sales of its therapeutic applications.
Keywords: Digital therapeutics, overactive bladder, pelvic health, mobile health, Prescription Digital Therapeutics, CeCe, healthcare providers, evidence-based, niche market, software applications.